2. Search Result
Search Result
Isoforms Recommended: CB1
Results for "

hCB1

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121541
    CB-25

    		Cannabinoid Receptor Cancer
    CB-25 is a ligand of CB1 cannabinoid receptors, acting as a partial agonist. CB-25 enhances Forskolin (HY-15371)-induced cAMP formation in cancer cells but not hCB1-CHO cells [1].
    CB-25
  • HY-118140
    ZCZ011

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    ZCZ011 is a potent and brain penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain [1].
    ZCZ011
  • HY-14788
    Drinabant

    AVE1625

    		 Cannabinoid Receptor Metabolic Disease
    Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R [1].
    Drinabant
  • HY-150029
    CB1/2 agonist 3

    		Cannabinoid Receptor Neurological Disease
    CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with Ki values of 5.9 nM and 3.5 nM, respectively [1].
    CB1/2 agonist 3
  • HY-145196
    RTICBM-189

    		Cannabinoid Receptor Neurological Disease
    RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca 2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats [1].
    RTICBM-189
  • HY-113591
    CB2 receptor agonist 10

    		Cannabinoid Receptor Others
    CB2 receptor agonist 10 is a CB2 receptor agonist with a Ki of 3.7 nM for hCB2, a Ki of 110 nM for hCB1, and an EC50 of 0.52 nM for hCB2 [1].
    CB2 receptor agonist 10
  • HY-144827
    AM8936

    		Cannabinoid Receptor Neurological Disease Metabolic Disease
    AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc [1].
    AM8936
  • HY-150030
    CB1/2 agonist 4

    		Cannabinoid Receptor Neurological Disease
    CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC50 values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with Ki values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC50 and EC50 is 0.8 μM and 0.12 μM, respectively [1].
    CB1/2 agonist 4
  • HY-103330
    TC-C 14G

    		Cannabinoid Receptor Neurological Disease
    TC-C 14G (Compd 14g) is a Cannabinoid-1 Receptor (CB1R) inverse agonist, with a Ki of 4 nM and EC50 of 11 nM for HCB1R, respectively [1].
    TC-C 14G
  • HY-151107
    CBR Agonist-2

    		Cannabinoid Receptor Neurological Disease
    CBR Agonist-2 is a CB1 agonist (CB1R; CB1 ligand) with an EC50 and a Ki of 960 nM and 970 nM, respectively. CBR Agonist-2 is a promising tool for investigating the involvement of hCB1R in disorders associated with the endocannabinoid system [1].
    CBR Agonist-2
  • HY-144705
    GAT564

    		Cannabinoid Receptor Neurological Disease
    GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC50s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma [1].
    GAT564

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: